Gilteritinib (Xospata; Astellas Pharma US, Inc., Northbrook, IL, USA), a FLT3 inhibitor, was approved by the FDA in 2018 and the EMA in 2019 for adults with relapsed/refractory FLT3‐mutated AML.36, 58. Here, FLT3 is linked to acute myeloid leukemia.